362 related articles for article (PubMed ID: 20829826)
21. Market watch: Sales of biologics to show robust growth through to 2013.
Goodman M
Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
[No Abstract] [Full Text] [Related]
22. Brand biologics grab 12 years' exclusivity, for now.
Osborne R
Nat Biotechnol; 2009 Aug; 27(8):677-8. PubMed ID: 19668153
[No Abstract] [Full Text] [Related]
23. Cheaper clinical trials: the real solution to the biologic industry's Gordian knot.
Montas A
Am J Law Med; 2011; 37(1):172-93. PubMed ID: 21614998
[No Abstract] [Full Text] [Related]
24. World Generic Medicines Congress Americas--a Health Network Communications Conference. 18-21 November 2008, Washington DC, USA.
Bowman M
IDrugs; 2009 Feb; 12(2):92-4. PubMed ID: 19204881
[No Abstract] [Full Text] [Related]
25. Biopharmaceutical benchmarks 2018.
Walsh G
Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
[No Abstract] [Full Text] [Related]
26. Appropriate specifications at the IND stage.
Geigert J
Dev Biol Stand; 1997; 91():39-43. PubMed ID: 9413681
[TBL] [Abstract][Full Text] [Related]
27. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
28. Pharma swept up in biogenerics gold rush.
Ratner M
Nat Biotechnol; 2009 Apr; 27(4):299-301. PubMed ID: 19352348
[No Abstract] [Full Text] [Related]
29. Biopharmaceutical benchmarks 2014.
Walsh G
Nat Biotechnol; 2014 Oct; 32(10):992-1000. PubMed ID: 25299917
[No Abstract] [Full Text] [Related]
30. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
Kuhrt K
IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
[TBL] [Abstract][Full Text] [Related]
31. Gearing up for follow-on biologics.
Hughes B
Nat Rev Drug Discov; 2009 Mar; 8(3):181. PubMed ID: 19247295
[No Abstract] [Full Text] [Related]
32. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
33. Generics, Supergenerics and Patent Strategies--SMi's 13th Annual Meeting.
Edwards C
IDrugs; 2010 Jul; 13(7):433-6. PubMed ID: 20582864
[TBL] [Abstract][Full Text] [Related]
34. Buy buy bispecific antibodies.
Holmes D
Nat Rev Drug Discov; 2011 Oct; 10(11):798-800. PubMed ID: 22037028
[No Abstract] [Full Text] [Related]
35. Why an abbreviated FDA pathway for biosimilars is overhyped.
Miller HI
Nat Biotechnol; 2011 Sep; 29(9):794-5. PubMed ID: 21904318
[No Abstract] [Full Text] [Related]
36. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
Arnold DG; Troyer JL
J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
[TBL] [Abstract][Full Text] [Related]
37. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry.
Kuhrt K
IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329
[No Abstract] [Full Text] [Related]
38. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
39. Correcting Hatch-Waxman.
Fernandes M
Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
[No Abstract] [Full Text] [Related]
40. [Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
Mellstedt H
Lakartidningen; 2009 Jun 3-9; 106(23):1563-6. PubMed ID: 19583014
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
